NGF/TrkA Signaling as a Therapeutic Target for Pain
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Nerve growth factor (NGF) was first discovered approximately 60 years ago by Rita Levi‐Montalcini as a protein that induces the growth of nerves. It is now known that NGF is also associated with Alzheimer's disease and intractable pain, and hence, it, along with its high‐affinity receptor, tropomyosin receptor kinase (Trk) A, is considered to be 1 of the new targets for therapies being developed to treat these diseases. Anti‐NGF antibody and TrkA inhibitors are known drugs that suppress NGF/TrkA signaling, and many drugs of these classes have been developed thus far. Interestingly, local anesthetics also possess TrkA inhibitory effects. This manuscript describes the development of an analgesic that suppresses NGF/TrkA signaling, which is anticipated to be 1 of the new methods to treat intractable pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nerve Growth Factor Treatment After Brain Injury Prevents Neuronal Death
Kromer, L. F. (1987) · Science · doi:10.1126/science.3798108 · Cited by 932 · cited 1×
“Due to its nerve-growing properties, NGF gained interest in the late 1980s as a candidate target for a therapeutic agent for central and peripheral nervous system disorders, and a study that administered NGF into animals was conducted.(16) This study revealed that”
Background
Cited by
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Current understanding of osteoarthritis pathogenesis and relevant new approaches
Tong, L., Yu, H., Huang, X., Shen, J., Xiao, G., Chen, L., Wang, H., Xing, L., & Chen, D. (2022) · Bone Research · doi:10.1038/s41413-022-00226-9 · Cited by 437
A novel human pain insensitivity disorder caused by a point mutation in ZFHX2
Habib, A. M., Matsuyama, A., Okorokov, A. L., Santana-Varela, S., Bras, J. T., Aloisi, A. M., Emery, E. C., Bogdanov, Y. D., Follenfant, M., Gossage, S. J., et al. (2018) · Brain · doi:10.1093/brain/awx326 · Cited by 50
Mahajan, A. T., Shivani, Datusalia, A. K., Coluccini, C., Coghi, P., & Chaudhary, S. (2024) · Molecules · doi:10.3390/molecules29153560 · Cited by 12
“…involved in cancer metastasis but also in various other diseases such as asthma [45], interstitial cystitis [46], inflammatory diseases such as ulcerative colitis and Crohn’s disease [47], atopic dermatitis [48], eczema and psoriasis [49], pain [50], Alzheimer’s disease [51], and inflammation [52].”
Background
Metadata
- Authors
- Hirose, M., Kuroda, Y., & Murata, E.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2015-08-27
- Volume
- 16
- Issue
- 2
- Pages
- 175-182
- ISSN
- 1530-7085 (ISSN-L)
- 1533-2500
- OpenAlex
- W1864822730
- Cited by
- 140
- References
- 1
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.